Literature DB >> 18985306

Neuroenhancement: status quo and perspectives.

Claus Normann1, Mathias Berger.   

Abstract

Neuroenhancement is a pharmacological attempt to increase cognitive performance in healthy humans. Strategies to improve learning and memory aim at plasticity pathways in the brain; phosphodiesterase inhibitors such as rolipram and NMDA-modulating drugs like donepezil and D: -cycloserine have been tested in clinical trials. Modafinil and methylphenidate are used to increase attention and vigilance. Other fields of intense research include mood, social interaction and sexual performance. So far, all clinical trials of neuroenhancing drugs have either failed or demonstrated only very limited efficacy. However, the high demand for neuroenhancement and the intense research efforts might come up with more efficacious drugs in the near future implying the need for an extended ethical discussion in society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18985306     DOI: 10.1007/s00406-008-5022-2

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  20 in total

1.  Enhanced long-term synaptic depression in an animal model of depression.

Authors:  Roman Holderbach; Kristin Clark; Jean-Luc Moreau; Josef Bischofberger; Claus Normann
Journal:  Biol Psychiatry       Date:  2006-12-04       Impact factor: 13.382

2.  Learning induces long-term potentiation in the hippocampus.

Authors:  Jonathan R Whitlock; Arnold J Heynen; Marshall G Shuler; Mark F Bear
Journal:  Science       Date:  2006-08-25       Impact factor: 47.728

Review 3.  Mammalian neural stem cells.

Authors:  F H Gage
Journal:  Science       Date:  2000-02-25       Impact factor: 47.728

Review 4.  Targeting the CREB pathway for memory enhancers.

Authors:  Tim Tully; Rusiko Bourtchouladze; Rod Scott; John Tallman
Journal:  Nat Rev Drug Discov       Date:  2003-04       Impact factor: 84.694

5.  Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear.

Authors:  Kerry J Ressler; Barbara O Rothbaum; Libby Tannenbaum; Page Anderson; Ken Graap; Elana Zimand; Larry Hodges; Michael Davis
Journal:  Arch Gen Psychiatry       Date:  2004-11

6.  Associative long-term depression in the hippocampus is dependent on postsynaptic N-type Ca2+ channels.

Authors:  C Normann; D Peckys; C H Schulze; J Walden; P Jonas; J Bischofberger
Journal:  J Neurosci       Date:  2000-11-15       Impact factor: 6.167

7.  Relative lack of cognitive effects of methylphenidate in elderly male volunteers.

Authors:  Danielle C Turner; Trevor W Robbins; Luke Clark; Adam R Aron; Jonathan Dowson; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2003-05-07       Impact factor: 4.530

8.  Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path.

Authors:  T V Bliss; T Lomo
Journal:  J Physiol       Date:  1973-07       Impact factor: 5.182

9.  Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist.

Authors:  James G Pfaus; Annette Shadiack; Tanya Van Soest; Maric Tse; Perry Molinoff
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-28       Impact factor: 11.205

10.  Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.

Authors:  Catherine J Harmer; Nicholas C Shelley; Philip J Cowen; Guy M Goodwin
Journal:  Am J Psychiatry       Date:  2004-07       Impact factor: 18.112

View more
  27 in total

1.  Cognitive-enhancing substance use at German universities: frequency, reasons and gender differences.

Authors:  Stefanie Mache; Patrick Eickenhorst; Karin Vitzthum; Burghard F Klapp; David A Groneberg
Journal:  Wien Med Wochenschr       Date:  2012-06-16

Review 2.  [Neuroethics in clinical practice].

Authors:  H Krug
Journal:  Nervenarzt       Date:  2009-08       Impact factor: 1.214

Review 3.  [Neuro-enhancement from an addiction specialist's viewpoint].

Authors:  M Soyka
Journal:  Nervenarzt       Date:  2009-07       Impact factor: 1.214

Review 4.  [Neuro-enhancement. Brain doping].

Authors:  H Förstl
Journal:  Nervenarzt       Date:  2009-07       Impact factor: 1.214

Review 5.  [Options, limits and ethics of pharmacological neuroenhancement].

Authors:  C Normann; J Boldt; G Maio; M Berger
Journal:  Nervenarzt       Date:  2010-01       Impact factor: 1.214

6.  Time to address stimulant abuse on our campuses.

Authors:  Daniel Rosenfield; Paul C Hébert; Matthew B Stanbrook; Ken Flegel; Noni E MacDonald
Journal:  CMAJ       Date:  2011-09-06       Impact factor: 8.262

7.  Retinoic acid as target for local pharmacokinetic interaction with modafinil in neural cells.

Authors:  Julian Hellmann-Regen; Karen Gertz; Ria Uhlemann; Michael Colla; Matthias Endres; Golo Kronenberg
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-21       Impact factor: 5.270

8.  Exposure to an enriched environment accelerates recovery from cerebellar lesion.

Authors:  Francesca Foti; Daniela Laricchiuta; Debora Cutuli; Paola De Bartolo; Francesca Gelfo; Francesco Angelucci; Laura Petrosini
Journal:  Cerebellum       Date:  2011-03       Impact factor: 3.847

9.  The Impact of Chronic Early Administration of Psychostimulants on Brain Expression of BDNF and Other Neuroplasticity-Relevant Proteins.

Authors:  Yaarit Simchon Tenenbaum; Abraham Weizman; Moshe Rehavi
Journal:  J Mol Neurosci       Date:  2015-07-08       Impact factor: 3.444

10.  Methylphenidate as a cognitive enhancer in healthy young people.

Authors:  Silmara Batistela; Orlando Francisco Amodeo Bueno; Leonardo José Vaz; José Carlos Fernandes Galduróz
Journal:  Dement Neuropsychol       Date:  2016 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.